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Abstract
Background:  The emergence of drug-resistant tuberculosis (TB) hampers TB control. Ten
provinces in China performed drug resistance surveys among tuberculosis (TB) patients in 1996–
2004 to assess levels of drug resistance.
Methods: Provincial drug resistance surveys included all isolates from newly diagnosed, smear-
positive TB patients. Drug susceptibility testing (DST) against isoniazid, rifampicin, streptomycin
and ethambutol was carried out in the provincial laboratories. For purposes of quality assurance, a
random sample (11.6%) was re-tested by the national reference laboratory (NRL).
Results:  Of 14,059 patients tested 11,052 (79%) were new TB cases. The weighted mean
prevalence of multi-drug resistant tuberculosis (MDR-TB) among all cases was 9.3% (range 2.2%–
10.4%); 5.4% (range 2.1% – 10.4%) among new cases and 25.6% (range 11.7%–36.9%) among
previously treated cases. Adjusting the drug resistance proportions using the re-testing results did
not change the estimated national mean prevalence significantly. However, in some individual
provinces the estimated resistance proportions were greatly influenced, especially among re-
treatment patients.
Conclusion: MDR-TB levels varied greatly between provinces in China, but on average were high
compared to the global estimated average of 4.8%. This study shows the importance of quality-
assured laboratory performance. Programmatic management of drug-resistant TB, including high
quality DST for patients at high risk of resistance and treatment with second-line drugs, should
become the standard, especially in high MDR-TB settings.
Introduction
The emergence of resistance to drugs used to treat tubercu-
losis, and particularly multi-drug resistant tuberculosis
(MDR-TB) [1], has become a significant public health
problem in a number of countries and an obstacle to
effective global TB control. The emergence of drug resist-
ant Myobacterium tuberculosis is associated with ineffective
treatment of tuberculosis, leading to acquired resistance
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and transmission of drug-resistant strains. With an esti-
mated MDR-TB proportion of 4.8% among incident TB
cases globally, almost half a million (489,139 (95% CI
455,093–614,215)) cases of MDR-TB are estimated to
emerge world-wide every year [1].
Treatment of MDR-TB, requires use of costly, toxic and
less effective second-line drugs for at least 18 months
because the bacilli are resistant to the most effective first-
line drugs rifampcin and isoniazid [2]. In case of exten-
sively drug-resistant TB (XDR-TB), i.e. MDR-TB with addi-
tional resistance to any fluoroquinolone and at least one
of the three injectable second-line anti-TB drugs (i.e. ami-
kacin, kanamycin, capreomycin), treatment options are
seriously limited[3]. The first estimates indicate that about
10% of all MDR-TB isolates meet the criteria for XDR-TB
[4].
China has the second largest number of TB cases in the
world [5], and also is one of the countries with high levels
of drug resistant TB [1]. Based on the data of the 4th
national TB epidemiological survey in 2000 [6], it is esti-
mated that there were 4.5 million prevalent TB cases in
China, of which 1.96 million were pulmonary, bacterio-
logically confirmed cases. The observed MDR-TB preva-
lence was 10.7%, so it was estimated that there were
209,720 (95% CI 149,159–270,841) cases of pulmonary,
bacteriologically confirmed MDR-TB. The magnitude and
pattern of drug resistance may vary per region because of
the huge size of the country, the diverse population den-
sity, and the unbalanced economic development in
China. However, the sample size of the national survey
was too small to be able to stratify the data per province.
In order to obtain insight into the prevalence and distri-
bution of resistance to anti-TB drugs, China has joined the
global project on anti-tuberculosis drug resistance surveil-
lance organized by World Health Organization and Inter-
national Union Against Tuberculosis and Lung Disease
(WHO/IUATLD) [1]. By 2007, 13 out of 31 provinces
with sufficient laboratory quality and capacity have con-
ducted drug resistance surveys. Ten provinces have
obtained final results, covering 38% (483 million out of
1.27 billion inhabitants) of the total Chinese population.
Results have been published before, but not in the inter-
national scientific literature [1,7-15]. Here we give an
overview of the results of the drug resistance surveys con-
ducted in ten provinces in China between 1996 and 2004.
Moreover, we have adjusted the estimates taking into
account re-testing results of a random sample (11.6%) of
all isolates from those provincial surveys.
Methods
Sampling method
For all surveys, the number of new smear positive cases to
be included per province was calculated according to the
sampling method in "Guidelines for surveillance of drug
resistance in tuberculosis" developed by WHO/IUATLD
[16], whereby the precision was set at 1.5%, and the initial
drug-resistance rate of one drug in past survey was set at
2.7% based on the proportion of rifampicin resistant iso-
lates among new patients in the 1990 national TB epide-
miological survey [6]. As recommended, this sample size
was multiplied by 2 to take into account the cluster sam-
pling method, and 15% was added to take losses into
account. The required intake period was estimated based
on the number of newly diagnosed new smear positive
cases in the previous year. All previously treated cases
diagnosed during the inclusion period were also included
in the surveys.
Beijing and Shanghai municipalities included all smear-
positive cases occurring, while the other provinces used
cluster-based sampling. In these province 30 (40 in
Guangdong) counties or districts were randomly selected,
and all smear-positive cases diagnosed in these sites dur-
ing the study period were included. Table 1 shows the
basic sampling information of the 10 provinces that have
finished a survey. Henan province has performed two sur-
veys, data from both rounds are included in this overview.
The results described here are marginally different from
those reported in the WHO/IUATLD report on drug resist-
ance [1], due to the fact that for some provinces incom-
plete results were reported to WHO.
Intake of patients
In all surveys, each newly registered TB patient, positive
on sputum smear microscopy, was interviewed by the cli-
nician using the standard WHO questionnaire to obtain
the treatment history. The treatment history of included
cases was classified by medical staff into new and previ-
ously treated cases using the WHO questionnaire for
interviewing patients and by checking the available medi-
cal documents of the patient. In all surveys, new patients
were defined as patients who had never received anti-
tuberculosis treatment or had received previous treatment
for less than a month. Previously treated patients were
defined as those having previously received anti-TB treat-
ment for more than 30 days. Patients in Henan (1996)
and Liaoning (1999) were reinterviewed to check the
treatment history after DST results became available and
showed unexpectedly high MDR-rates among new cases.
Laboratory methods
The two smears with the highest bacterial counts were cul-
tured, and one culture was submitted for DST. Smear
microscopy and culture was performed in the county or
district laboratory (except for the 1996 Henan survey,
where culture was done at the provincial level), while drug
resistance testing was done at the provincial level. Ziehl-
Neelsen staining was used for sputum smear microscopy.BMC Infectious Diseases 2008, 8:166 http://www.biomedcentral.com/1471-2334/8/166
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Sputum smear microscopy positive samples were cultured
on Lowenstein-Jensen (LJ) culture medium. M. tuberculo-
sis complex was identified by also culturing on LJ medium
containing p-nitrobenzoic acid (PNB), where growth
indicates the bacilli which are not part of the M. tuberculo-
sis  complex. The samples containing non-tuberculosis
mycobacteria were excluded from this study. Drug suscep-
tibility testing was performed on LJ medium impregnated
with isoniazid (INH), rifampicin (RIF), streptomycin
(SM), and ethambutol (EMB) according to the proportion
method as recommended by WHO/IUATLD [1,16]. The
concentration of anti-TB drugs used was 0.2 mg/L for
INH, 40 mg/L for RIF, 2 mg/L for EMB, and 4 mg/L for SM.
Multi-drug resistant (MDR) TB was defined as isolates
being resistant to both RIF and INH.
Laboratory quality control
External QA for smear and culture in county and district
level laboratories was conducted by the prefectural and
provincial TB laboratories based on the WHO guideline
[16]. For internal quality assurance (QA) on DST, a stand-
ard H37Rv strain was included for each new batch of LJ
medium. External QA on DST included proficiency testing
of the National Reference Laboratory (NRL) and provin-
cial reference laboratories before the start of the survey by
the supranational laboratory (SRL), and blinded re-testing
of a random selection of approximately 10% of the iso-
lates from each province by the NRL of China during the
survey. Before 2002, the serving SRL for China was the
Korean Institute of Tuberculosis; afterwards the Public
Health Laboratory Hong Kong fulfilled this function.
Data management and analysis
Data were double entered and discrepancies were checked
against the raw data. The proportion of resistant isolates
per province was calculated. The weighted mean preva-
lence of resistance for the ten provinces was calculated by
weighting the observed prevalence of resistance by the
number of notified smear-positive TB cases per province
in 2006. For Henan province, only the estimates from the
most recent survey (2001) were used.
For the isolates retested by the NRL, aggregated results on
concordance between provincial and NRL DST results
were available. We calculated concordance for all isolates
together and separately for the isolates considered suscep-
tible and for the isolates considered resistant to a particu-
lar drug according to the provincial laboratory.
Comparative results of the NRL after re-testing about 10%
of the isolates per province were used to estimate the
adjusted provincial resistance proportions per drug, for
new, previously treated and combined cases separately. To
this end, the ratio of the proportion of resistant strains
among all re-tested strains according to the provincial lab-
oratory over the proportion of resistant strains among all
re-tested strains according to the NRL was calculated. A
ratio over unity indicates that the provincial laboratory
overestimated the resistance proportion, and a ratio
below unity indicates it underestimated resistance. The
proportion of resistant strains among all isolates tested by
the provincial laboratory was divided by this ratio to esti-
mate the adjusted provincial resistance proportions to the
individual drugs. The ratio was applied separately to new
and previously treated cases. This estimation assumes that
the results of the NRL are the gold standard, that the 10%
sample re-tested is representative of all isolates with
regard to observed differences between the provincial and
reference laboratory.
Ethical issues
All provincial surveys were approved by the Ministry of
Health of China. Patients were asked for written informed
consent before interviewing, and collecting three sputum
samples. The DST results were communicated to the treat-
ing physicians. The decision to change the treatment
based on the DST results was left to the treating physician.
Table 1: Sampling information for the 10 provinces of which final results of one or more drug resistance surveys are available in 2008
Province Year Population 
(*million)
No. of counties/
districts
No. of reported SS+ 
cases in year of 
survey
No. of survey 
sites
New cases Previously treated cases
n( % ) n ( % )
Henan 1996 91.0 157 11,822 30 646 (47) 726 (53)
Shandong 1997 86.5 141 18,488 30 1009 (82) 220 (18)
Zhejiang 1998 43.9 89 6,278 30 809 (85) 145 (15)
Guangdong 1998 69.0 113 26,200 40 1482 (90) 166 (10)
Hubei 1999 57.9 88 23,633 30 859 (78) 238 (22)
Liaoning 1999 40.9 100 8,002 30 818 (90) 86 (10)
Henan 2001 95.6 157 14,680 30 1222 (82) 265 (18)
Inner Mongolia 2001 23.8 101 3,564 30 876 (69) 386 (31)
Beijing 2004 14.2 18 730 All 1043 (87) 154 (13)
Shanghai 2004 13.3 19 2,958 All 764 (79) 200 (21)
Heilongjiang 2004 38.1 87 21,560 30 1574 (79) 421 (21)BMC Infectious Diseases 2008, 8:166 http://www.biomedcentral.com/1471-2334/8/166
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Results
The total number of patients included in the eleven drug
resistance surveys in ten provinces was 14,059, of which
11,052 (79%) were new TB cases (Table 1).
Drug resistance
Drug resistance levels are shown in Table 2. The weighted
mean prevalence of any drug resistance in the ten prov-
inces was 24.3% (range 14.8% – 42.1%) among new cases
and 51.8% (range 27.5% – 67.5%) among previously
treated cases.
There were considerable differences in resistance propor-
tions between provinces for the individual drugs, but the
trend was the same in all provinces. In new cases, on aver-
age resistance proportions were highest for streptomycin
(16.4%) and isoniazid (14.0%), intermediate for
rifampicin (7.2%) and lowest for ethambutol (3.3%). In
previously treated cases, average resistance proportions
were lowest for ethambutol (14.5%), intermediate for
streptomycin (31.1%) and rifampicin (31.5%), and high-
est for isoniazid (39.2%).
The weighted mean MDR prevalence was 5.4% (range
2.1% – 10.4%) among new patients and 25.6% (range
11.7% – 36.8%), among previously treated patients. The
individual MDR prevalence among new and previously
treated cases are shown in Figure 1. Four out of the ten
provinces observed over 6.5% of MDR among new cases,
with this cut-off previously being defined as a MDR
hotspot [2]. The four provinces Henan (in both surveys),
Zhejiang, Inner Mongolia and Heilongjiang reported
MDR prevalences of over 20% in previously treated cases.
Both in Henan (1996 survey) and Liaoning (1999),
reinterviews of patients indicated that an estimated 25–
30% misclassification of previously treated cases as new
cases had occurred, so the prevalence of MDR among new
TB cases is more likely to be around 11% instead of 16%
in Henan (1996) [1,17] and 8% instead of the reported
10% in Liaoning [1].
Re-testing results
The re-testing results on drug resistance by the NRL were
available for the seven surveys performed in and after
1999. A total number of 1,033 isolates were re-tested,
reflecting 11.6% of the isolates from these seven surveys.
The number of provincial re-tested isolates varied
between 94 and 268. Overall concordance between the
provincial and national DST results on whether an isolate
was resistant or susceptible was quite high: the median
was 94.7%, 97.1%, 93.8% and 97.1%, for INH, RIF, SM
and EMB, respectively. Concordance for susceptibility was
usually over 90% in the provincial laboratories (Figure 2):
the medians were 97.7%, 98.9%, 96.3%, and 98.9%,
respectively. However, concordance for resistance was
rather low for several drugs in several provincial laborato-
ries: the medians were 93.4%,, 88.9%, 87.2% and 57.1%,
respectively. As a consequence, Hubei, Henan and Inner
Mongolia provincial laboratories overestimated resistance
proportions for all four drugs while Liaoning, Hei-
longjiang and Beijing provinces underestimated resistance
proportions for three out of four drugs. In Shanghai labo-
ratories, RIF resistance was overestimated and EMB resist-
ance underestimated (see Figure 2).
The weighted means of prevalence of drug resistance pro-
portions over all provinces, based on re-testing by the
NRL, were hardly affected, but in some provinces resist-
ance proportions were greatly influenced. In Henan
(2001) and Inner Mongolia, adjusted resistance propor-
tions for RIF, the most important predictor for MDR,
decreased by approximately 2% in new cases and 10% in
previously treated cases. For previously treated cases, the
Table 2: Observed drug resistance in new, previously treated (PT) and all tuberculosis cases in different provinces in China
Province Resistance to
Any drug Rifampcin Isoniazid Ethambutol Streptomycin MDR-TB
New PT All New PT All New PT All New PT All New PT All New PT All
Henan (1996) 35.0 66.0 51.4 14.6 43.5 23.9 24.0 48.8 37.1 7.7 18.9 13.6 26.0 50.7 39.1 10.8 34.4 23.3
Shandong 17.6 50.0 23.4 3.8 23.2 7.2 11.3 40.5 22.4 1.7 10.5 6.8 12.2 34.5 25.9 2.9 19.6 5.9
Zhejiang 14.8 59.3 21.6 6.4 44.4 12.2 11.2 51.4 17.5 4.7 18.0 6.8 8.9 34.2 12.8 4.5 34.5 9.0
Guangdong 18.0 33.7 20.2 7.1 19.9 8.7 11.4 22.3 12.5 3.6 7.8 4 9.3 16.9 10.1 5.3 15.7 6.6
Hubei 17.5 44.5 23.3 3.8 26.9 8.8 9.7 33.2 14.8 0.6 8.8 2.4 11.4 25.6 14.5 2.1 21.8 6.4
Liaoning 42.1 55.8 43.3 11.4 29.1 13.1 25.3 41.9 26.9 3.8 14.0 4.8 34.1 41.9 34.8 10.4 24.2 11.7
Henan (2001) 29.8 60.8 35.5 9.6 42.6 15.5 17.0 47.2 22.4 4.3 18.1 6.8 22.2 43.0 25.9 7.8 36.6 12.9
Inner Mongolia 35.7 65.3 44.8 9.6 45.3 20.5 20.3 56.5 30.3 8.9 31.8 15.3 21.3 29.9 23.7 7.0 36.8 16.1
Beijing 17.9 35.1 20.1 4.2 14.9 5.6 8.7 24.7 10.8 4.1 9.1 4.8 9.1 21.4 10.7 2.3 11.7 3.5
Shanghai 15.4 27.5 17.9 4.8 15.0 7.0 11.7 21.5 13.3 3.0 10.0 4.5 8.1 12.5 9.0 3.9 12.5 5.7
Heilongjiang 36.1 67.9 42.8 10.6 40.4 16.9 16.9 48.0 23.6 5.9 24.5 9.8 24.3 32.3 26.0 7.2 30.4 12.1
Weighted mean* 24.3 51.8 29.5 7.2 31.5 11.8 14.0 39.2 19.6 3.3 14.5 6.0 16.4 31.1 20.5 5.4 25.6 9.3
* the weighted mean for the 10 provinces excludes 1996 Henan dataBMC Infectious Diseases 2008, 8:166 http://www.biomedcentral.com/1471-2334/8/166
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estimated RIF resistance proportions decreased from 43%
and 45% to 32% and 36% respectively. On the other
hand, RIF resistance proportions were underestimated in
Beijing laboratories: taking into account re-testing results,
RIF resistance was adjusted from 4.2% to 5.3% in new
cases and from 14.9% to 19.0% in previously treated
cases. Due to relatively small numbers, these differences
will not be statistically significant, but they do indicate the
direction and magnitude in which resistance proportions
were under- or overestimated in the different provinces.
Discussion
The results of the provincial drug resistance surveys show
that the prevalence of drug resistance varied greatly
between the provinces, but on average was worryingly
high with a weighted mean for MDR-TB of 9.3% among
all cases; 5.4% among new cases and 25.6% among previ-
ously treated cases. The global MDR-TB estimates are
4.8% for all cases, 3.1% for new cases and 19.3% for pre-
viously treated cases. Provinces with the highest resistance
rates were Henan, Liaoning, Inner Mongolia and Hei-
longjiang. The latter two are bordering the former Russian
MDR-TB proportions among new and previously treated cases observed in the provincial drug resistance surveys Figure 1
MDR-TB proportions among new and previously treated cases observed in the provincial drug resistance sur-
veys.BMC Infectious Diseases 2008, 8:166 http://www.biomedcentral.com/1471-2334/8/166
Page 6 of 8
(page number not for citation purposes)
Federation, where resistance levels are known to be
extremely high [1,18]. and Liaoning is bordering these
two provinces. Henan however, is located in the middle of
China and borders two provinces with clearly lower MDR-
TB levels. Therefore, it is necessary to gain insight into the
distribution of drug resistance levels in all provinces of
China.
What is new in the results presented in this paper is that
we adjusted estimates of drug resistance based on re-test-
ing by the NRL. Unfortunately, retesting results on an
individual level were not available. With the available
aggregated results we were able to show that overall high
agreement between resistance proportions may conceal
insufficient agreement for resistant and susceptible iso-
lates separately. As provincial results counterbalanced
each other, the adjusted estimates hardly affected the esti-
mated national mean prevalence of drug resistance. How-
ever, in some individual provinces resistance proportions
were greatly influenced. Adjustments were proportional,
therefore, resistance percentages in previously treated
cases were affected the most in absolute figures as in this
group resistance percentages were highest. As resistance
patterns for individual isolates in the provincial and
national reference laboratory were not available, it was
not possible to estimate adjusted MDR prevalences. How-
ever, as rifampicin resistance has been proven to be a good
marker for MDR in many countries, provincial MDR levels
will need to be adjusted in the same direction.
In Henan (1996) and Zhejiang, the then running policy
was that re-treatment was not fully free of charge. This
may have precluded patients from disclosing their treat-
ment history. As a consequence, results from the two sur-
veys in Henan may not be directly comparable. Surveys
following the Liaoning survey in 1999 have had more
elaborate checking of treatment status built in and in gen-
eral survey protocols have been more closely followed
Re-testing results by the national reference laboratory on a random selection of the isolates as tested by the provincial labora- tories Figure 2
Re-testing results by the national reference laboratory on a random selection of the isolates as tested by the 
provincial laboratories. Concordance between provincial laboratories and the national reference laboratory for isolates 
tested resistant by the provincial laboratory is shown by light bars, for isolates tested susceptible by dark bars. The adjustment 
ratio (￿) indicates the amount of over- or underestimation of resistance by the provincial laboratory (ratio above unity indi-
cates overestimation).
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with regard to both survey methods and laboratory meth-
ods. In the period 1992–2001, China has implemented
the TB Control Project, funded by a World Bank loan. This
project covers 13 provinces, and provides treatment free
of charge to both new and previously treated cases. Since
2002, drugs are also free of charge for new cases and cases
with one previous treatment episode in the other prov-
inces. For smear-negative cases treatment is free of charge
in China from 2005 onwards.
Drug resistance proportions among new, and previously
treated TB cases are important indicators for TB epidemi-
ology. In a well functioning TB control program with low
levels of defaulting from treatment, high resistance levels
are expected among previously treated cases because drug
resistance is a strong risk factor for recurrent TB. This is
what we observed in China. However, if a good TB control
program is in place, also the proportion of previously
treated patients among all TB patients should be low. In
China the proportion of previously treated patients was
high on average, about 20%. Globally, the proportion of
previously treated patients is currently estimated to be
11% [5]. There is a well established relationship between
the proportion of retreatment cases and proportion of
MDR among new cases [8]. In our data we observed a
weak positive linear association (R2 = 0.18).
Many possible explanations for the development of drug
resistance in China exist, and different explanations may
prevail in different areas of this vast country. These
include the inadequate use of anti-TB drugs in public hos-
pitals, lack of supervision of treatment, poor drug man-
agement, and absence of infection control measures in
hospitals. Availability of anti-TB drugs without a prescrip-
tion in China in the past may have contributed to the
development of drug resistance.
In a situation where drug resistance testing is not done
routinely, as currently is the case in China, drug resistance
surveys are good tools to determine the magnitude of the
problem, meanwhile building laboratory capacity and
establishing continuous drug resistance surveillance. The
results should be the basis for development and imple-
mentation of interventions to reduce the problem of
resistance. In China, the results have contributed to intro-
duction of programmatic management of drug-resistant
TB (PMDT), using the GLC mechanism (Green Light
Committee for Access to second-line anti-tuberculosis
drugs), and supported by the Global Fund (GFATM). It
has been piloted in two provinces and a rapid expansion
in 14 more provinces is under preparation with a total of
15,011 MDR-TB cases in these 16 provinces.
In conjunction with the drug resistance surveys, a quality
assurance system including yearly proficiency testing of
provincial laboratories is evolving in China [16,17].
Therefore, we expect to find better agreement on DST
results between provincial laboratories and the NRL in
future drug resistance surveys within China. Improved
laboratory quality for DST obviously is also important for
individual patient management.
China is currently conducting a nationwide anti-TB drug
resistance survey. This will give insight into the overall
level of drug resistance in China. However, as the sample
size per province is too small for precise estimates of
resistance per province, it is also necessary to perform sep-
arate drug resistance surveys in the provinces that have not
done so yet. As there is a wide variation in observed drug
resistance between provinces, it is important that all prov-
inces in China conduct their own surveys, and repeat sur-
veys to allow for evaluation of trends. Provincial surveys
should also allow for differentiation between the different
retreatment categories (relapse, retreatment after default,
retreatment after failure). In future surveys, the rate of
XDR-TB in MDR-TB cases should also be determined in
order to inform MDR-TB treatment design.
Conclusion
Resistance levels vary greatly within China and are
unknown for a large part of the TB patient population.
However, on average MDR-TB levels are worryingly high.
PMDT, including routine, quality-assured DST for those
patients at high risk of resistance, especially failure cases,
and programmatic treatment with second-line drugs,
should become integrated on a routine basis within TB
control in the whole country of China, with priority for
high MDR-TB settings.
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